Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and Others Published 2022-10-24 Download video MP4 360p Download video MP4 720p Recommendations 01:42 What are Antibody Drug Conjugates (ADCs) 41:58 Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in NSCLC 27:03 Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology Conference 14:12 A breakthrough in eradicating cancer | Eric Tran | TEDxPortland 15:51 Introduction to Immunotherapy (Immunotherapy Documentary Part I) 58:27 Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies 05:15 Lung Cancer Treatment 05:20 Lung Cancer: 9 Common Treatment Options 1:14:48 Oncology Drug Modalities: A New Era in Oncology Drug Development 1:00:46 Triple Negative Breast Cancer Case Panel Discussion | 2022 Best of Breast Conference 1:09:19 Cancer immunotherapy - significant breakthrough or unrealised potential? 08:47 What's NEW in Breast Cancer Treatment in 2023 | Top Breast Cancer Docs Discuss Emerging Research 09:06 Chemo Sucks. Science Is Changing That 1:28:26 Cancer Metabolism: From molecules to medicine 05:03 Triple Negative Breast Cancer (TNBC) | Dr Rachel Dear 54:34 Cancer Immunotherapy: 2022 Research and a Look Ahead with E. John Wherry, Ph.D. 18:42 Antibody-drug Conjugate Bioanalytical Assay Development: Immunogenicity Challenge Presentation 56:17 Application of DOE Design of Experiments to Antibody Drug Conjugates ADC Process Development 1:20:51 NCCN Patient Webinar: Small Cell Lung Cancer 58:49 Curing metastatic solid tumours with immune checkpoint inhibitors by Professor James Larkin Similar videos 51:40 TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal 1:27:49 Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors 49:56 Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations 20:34 2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2 58:30 The Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC 50:09 Community Context: Integrating TROP2-Targeting ADCs Into Patient-Centric Breast Cancer Care 1:37:33 Amplifying the ADC Advantage: ADCs as the Next Frontier in Precision Lung Cancer Care 1:00:29 Answers to Key Questions About Antibody–Drug Conjugates in NSCLC 56:32 Antibody Drug Conjugates for Cancer 01:25 Promising new ADCs 01:13 HER3 as a New Target in the Oncology field 1:05:01 Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors 1:26:11 The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer 1:29:20 Experts discuss Antibody-Drug Conjugates in Breast, Lung, & GI Cancers - https://bit.ly/3rKKvzM 00:46 What does the future hold for ADCs in breast cancer? 00:44 ADCs in early breast cancer More results